Loading today’s stories

Today

AI-assisted reporting, grounded in a per-article claim ledger. Perspective Coverage and Reality Strip separate source viewpoints from evidence, adoption, hype, incentives, and confidence.

Today

Front Page
Today’s Briefing
Newsletters
Trending
For You
Discover
My Stack
Saved
Off Radar
Search

Sections

Security
Build
Invest
Product
Leadership
Science

Company

About
Mission
How this is made
Evidence Index
The desks
The sources we read
Corrections
Press and brand
The daily edition

Trending now

AI Copyright Litigation
Strategic Corporate Investment
LLM Evaluation
Post-Quantum Cryptography
US Manufacturing Reshoring
Generative Media Models
Launch Infrastructure
Starship Reusability
Capital Allocation
Industrial Site Risk

How this is made

Today For You My Stack Off Radar Search

Shingrix — other — Clarity Today

other

Shingrix

GlaxoSmithKline's recombinant herpes zoster (shingles) vaccine, introduced in 2017 and described in the source as the only shingles vaccine currently on the market.

Known aliases

recombinant shingles vaccine
recombinant zoster vaccine
RZV

Relationships

No evidence-backed relationships are recorded.

Current clusters

science1 distinct publisher

A 24% dementia gap, and 1.7% uptake: the shingles number nursing homes will be asked about

A Brown-led study of half a million nursing home admissions puts the shingles vaccine's dementia signal at 24%. It also shows that almost nobody in that population got the shot.

Publishers:sciencedaily.com

Reality

Evidence58
Adoption16
Hype gap+28
Incentives66

Confidence52